Drug profile · INN
lecanemab
LEQEMBI
lecanemab (LEQEMBI) is a beta amyloid a4 protein inhibitor.
Drug details — lecanemab
- Class
- Nervous system (N06)
- Route
- —
- Patents
- 0
- Programs
- 3
- Data quality
- 0.83
Quick answer
lecanemab (LEQEMBI) is a beta amyloid a4 protein inhibitor.
Key facts
Mechanism of action
Beta amyloid A4 protein inhibitor
Primary target: Amyloid-beta precursor protein
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | approved | — |
| PMDA | approved | — |
Recent coverage
Biogen and Eisai expand Leqembi access with subcutaneous maintenance dosing
Biogen and Eisai have expanded LEQEMBI access in the U.S. with subcutaneous maintenance dosing, following FDA approval of the BLA in August 2025. The move could improve convenience, reduce infusion-related burden, and shape investor expectations for Eisai and Biogen stock.
Eisai's Leqembi Sales Forecast: A Turning Point?
Structured plan for Eisai's Leqembi Sales Forecast: A Turning Point?
Eisai's Leqembi Sales Forecast: Projecting Blockbuster Status in Alzheimer's
Eisai projects significant growth for its Alzheimer's treatment, Leqembi, with sales forecasts indicating a strong path toward blockbuster status. This analysis explores the drivers behind this projection and its strategic implications for the pharmaceutical industry.
Eisai's Leqembi Sales Forecast: A Closer Look at $900M Potential
Eisai is making strides toward achieving blockbuster status for Leqembi, with a projected sales forecast of $900M. This article explores the implications for the pharmaceutical landscape.
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is lecanemab?
lecanemab (LEQEMBI) is a beta amyloid a4 protein inhibitor.
What is the brand name for lecanemab?
LEQEMBI is a marketed brand name for lecanemab. Check FDA Drugs@FDA for the current US label holder and prescribing information.